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Background. Changes in cardiopulmonary reserve and biomarkers related to wall stress, inflammation, and oxidative stress
concomitantly with the evaluation of peripheral arterial blood flow have not been investigated in patients with heart failure with
preserved ejection fraction (HFpEF) compared with healthy subjects (CTL). Methods and Results. Eighteen HFpEF patients and
14 CTL were recruited. Plasma levels of inflammatory and oxidative stress biomarkers were measured at rest. Brain natriuretic
peptide (BNP) was measured at rest and peak exercise. Cardiopulmonary reserve was assessed using an exercise protocol with gas
exchange analyses. Peripheral arterial blood flow was determined by strain gauge plethysmography. Peak VO
2
(12.0 ± 0.4 versus
19.1 ± 1.1mL/min/kg, 𝑃 < 0.001) and oxygen uptake efficiency slope (1.55 ± 0.12 versus 2.06 ± 0.14, 𝑃 < 0.05) were significantly
decreased in HFpEF patients compared with CTL. BNP at rest and following stress, C-reactive-protein, interleukin-6, and TBARS
were significantly elevated in HFpEF. Both basal and posthyperemic arterial blood flow were not significantly different between the
HFpEF patients andCTL.Conclusions. HFpEF exhibits a severe reduction in cardiopulmonary reserve and oxygen uptake efficiency
concomitantly with an elevation in a broad spectrum of biomarkers confirming an inflammatory and prooxidative status in patients
with HFpEF.
1. Introduction
Heart failure with preserved ejection fraction (HFpEF)
is associated with a decrease in cardiopulmonary reserve
leading to significant maladaptive changes in peripheral
arterial [1] and muscular functions [2]. Cardiopulmonary
reserve and oxygen uptake efficiency are both decreased in
chronic heart failure with reduced ejection fraction (HF-rEF)
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[3, 4]. Other small studies have demonstrated that the oxygen
uptake efficiency slope (OUES) is decreased in chronic HF
patients [5] and in older patients with HFpEF [6].
HFpEF is characterized by an increase in some biomark-
ers related to neurohumoral activation [7, 8]. Previous inves-
tigations have reported significant differences between
patients with HFpEF versus HF patients with reduced ejec-
tion fraction [7, 8] such as lower N-terminal prohormone of
brain natriuretic peptide (NT-proBNP) in HFpEF. The char-
acterization of changes in biomarkers at rest and following
peak exercise has not been fully addressed in this form of HF.
Similarly, disorders of endothelial function and peripheral
arterial blood flow have been a matter of controversies in
patients with HFpEF [1, 9–12]. No investigations have studied
the changes in biomarkers related to LV wall stress, subclin-
ical inflammation, and oxidative stress concomitantly with
the evaluation of cardiopulmonary reserve and peripheral
arterial function in HFpEF compared with healthy subjects.
The primary objective of this study was to investigate
the changes cardiopulmonary reserve and peripheral arterial
function, and biomarkers related to neurohumoral activation,
inflammation, and oxidative stress in patients with HFpEF
compared with healthy subjects.The secondary objective was
to explore the relationship between biomarkers and func-
tional capacity.
2. Methods
2.1. Study Population. This study was a prospective nonran-
domized investigation including both patients with HFpEF
and healthy subjects. Eighteen (18) patients and 14 healthy
subjects were recruited. Patients were included in the HFpEF
group if they had New York Heart Association (NYHA)
classes II and III symptoms and if they had a left ventricle
ejection fraction (LVEF) ≥50% measured by echocardiogra-
phy within the 12 months prior to enrolment in the study.
The diagnosis of HFpEF was confirmed by the presence of
at least one abnormality on the screening echocardiography
consistent with this condition such as atrial dilatation, left
ventricle (LV) concentric remodeling or hypertrophy, and/or
evidence of diastolic dysfunction by Doppler studies. LV vol-
umes and filling rates were further assessed by radionuclide
ventriculography at the beginning of the study. Patients with
symptomatic hypotension (systolic blood pressure (SBP) <
90mmHg) or poorly controlled hypertension (SBP ≥ 160
and/or diastolic blood pressure > 90mmHg) were excluded.
Similarly, patients with severe chronic pulmonary disease
limiting exercise capacity, severe renal failure (creatinine >
250𝜇mol/L), or significant liver dysfunction (transaminases
≥ 3-fold upper normal values) were excluded. Healthy sub-
jects were included if they presented with no significant
medical conditions and were on no medication at the time
of assessment. Subjects or patients presenting with acute
or active chronic inflammatory conditions were excluded
from this study. All patients and healthy subjects provided
written informed consent before undergoing any study-
related procedures. The investigation conforms to the prin-
ciples outlined in the Declaration of Helsinki. The study
was approved by the Montreal Heart Institute—Research
Scientific and Ethics Committees.
2.2. Maximal Exercise Testing. The maximal exercise test
was performed on a treadmill using a RAMP protocol [13].
Gas exchange parameters were measured breath by breath
during testing, and then averaged every 15 seconds for
minute ventilation (VE, L/min), O
2
uptake (VO
2
, L/min),
and CO
2
production (VCO
2
, L/min) using an automated
gas analyzer system (Oxycon Pro, Hoechberg, Germany)
[14]. Heart rate and manual brachial blood pressure were
recorded before the test and at 2-minute intervals during
exercise and recovery. Criteria for maximal effort were the
attainment of the primary maximal criteria, a leveling off
of oxygen uptake (<150mL/min) despite increased inten-
sity or one of the three secondary maximal criteria: (1) a
respiratory exchange ratio >1.05, (2) inability to maintain
walking, and (3) patient exhaustion due to fatigue or other
clinical symptoms (dyspnea, ECG, and/or blood pressure
abnormalities) [14]. The average value of the VO
2
recorded
during the last 15 seconds of exercise was considered as the
peak oxygen uptake (VO
2
peak), and VE/VCO
2
slope was
also determined. The oxygen uptake efficiency slope (OUES)
was calculated during exercise using the slope of the relation
VO
2
and the log of ventilation as previously reported [15].The
heart rate recovery (HRR) was measured at 1 (HRR 1) and 2
(HRR 2) minutes following the termination of exercise.
2.3. Biomarkers Measurements. Venous blood samples were
taken after semisupine rest for at least 15 minutes from both
experimental populations under fasting state in the morning.
Serum samples were centrifuged (1500 g, 15min, 4∘C) and
immediately frozen at −80∘C. Blood tests were performed in
the resting state for all parameters and within 2 minutes fol-
lowing peak exercise for the brain natriuretic peptide (BNP).
Neurohumoral activation was assessed by plasma lev-
els of both BNP and NT-proBNP. These two biomarkers
were measured by electrochemiluminescence immunoassay
using the Roche BNP and proBNP assays (Roche Diagnos-
tics, Mannheim, Germany) on the Elecsys 2010 analyzer
(Roche Diagnostics). Serum high-sensitivity C-reactive pro-
tein (hsCRP) was measured using the Dade Behring Cardi-
oPhase hsCRP assay (Siemens Healthcare Diagnostics Prod-
ucts, Marburg, Germany) on the BN ProSpec Nephelometer
(Siemens Healthcare Diagnostics Products). Plasma level of
thiobarbituric acid reactive substances (TBARS) was mea-
sured colorimetrically as previously described [16]. Plasma
levels of interleukin-6 (IL-6) and 8-epi-prostaglandin F2𝛼
were analyzed by ELISA using the R&D Systems kits (Min-
neapolis, MN, USA).
2.4. Strain Gauge Plethysmography (SGP). All measurements
of blood flow were performed 2 hours after morning med-
ications. Forearm basal arterial flow was assessed using the
strain gauge plethysmography (SGP) methods as previously
described [17]. Briefly, all subjects sat with their arms resting
in a supine position on supports positioned above the level
of the heart. Venous cuffs were then connected to automatic
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Table 1: Baseline characteristics of the study population.
Clinical variables HFpEF patients(𝑛 = 18)
Healthy controls
(𝑛 = 14)
Age (years) 70.7 ± 8.9∗ 61.7 ± 9.9
Male 5 (28%) 6 (43%)
Heart rate (bpm) 60.8 ± 8.9∗ 70.2 ± 7.7
Systolic blood pressure (mmHg) 125 ± 16 126 ± 18
Diastolic blood pressure (mmHg) 72.4 ± 8.2 76.3 ± 7.1
Duration of heart failure (months) 22.3 ± 24.2 —
NYHA functional class
II 15 (83%) 0 (0%)
III 3 (17%) 0 (0%)
Etiology of heart failure
Ischemic 3 (17%) 0 (0%)
Hypertension 15 (83%) 0 (0%)
Laboratory values
Haemoglobin (mg/L) 131 ± 13∗∗ 145 ± 12
Serum creatinine (𝜇mol/L) 106 ± 43∗ 79.7 ± 15.4
Medications
ACE inhibitors 1 (6%) 0 (0%)
ARBs 12 (67%) 0 (0%)
Beta-blockers 9 (50%) 0 (0%)
Radionuclide angiography
LVEF (%) 57.5 ± 7.0∗ 52.1 ± 6.2
LVEDV (mL) 118.3 ± 33.3∗ 98.0 ± 19.1
PFR (EDV/s) 1.95 ± 0.50∗ 2.34 ± 0.42
TPFR (ms) 182 ± 53∗ 147 ± 40
ACE: angiotensin-converting enzyme; ARBs: angiotensin II receptor blockers; LVEDV: left ventricle end-diastolic volume; PFR: peak filling rate of the left
ventricle; TPFR: time to peak filling rate of the left ventricle; LVEF: left ventricular ejection fraction; NYHA: NewYorkHeart Association. Continuous variables
are expressed as mean ± standard deviation and categorical variables as frequencies and percentages. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01.
pneumatic inflators (Hokanson, E-20 rapid cuff inflator;
Bellevue, WA) set to 50mmHg and calibrated strain gauges
were placed around both forearms and connected to a
plethysmograph (Hokanson, model EC-4, Bellevue, WA).
Baseline flowmeasurements were performed before and after
a 240-second period of arterial occlusion. Arterial inflow was
calculated by determining the upslope of strain gauge signals
calculated using a linear regression model.
2.5. Statistical Analyses. Continuous baseline characteristics
are expressed as mean ± standard deviation and categorical
variables as frequencies and percentages. A logarithmic
transformation was applied to variables showing a lognormal
distribution. The proportion of male was compared between
groups with a Chi-square test and continuous baseline
characteristics were compared using a Student’s 𝑡-test. All
measurements including parameters of cardiopulmonary
function, biomarkers, and arterial blood flow were analyzed
using ANCOVA or repeated measures ANCOVA including
age as a covariate to control for its potentially confounding
effect. Contrasts between groupswere performed at each time
point in the repeated measures model. Basal and hyperemic
arterial blood flows were summarized by computing area
under the curve. Results are expressed as adjusted means
± standard errors or adjusted geometric means. To evaluate
whether biomarkers influenced aerobic capacity, Pearson’s
correlationswere performed. A𝑃 value< 0.05was considered
statistically significant. Statistical analyses were performed
using the SAS software (version 9.2 or higher).
3. Results
A total of 32 subjects were recruited for this study including
18 patients with HFpEF and 14 healthy subjects. The clinical
characteristics of the study population are shown in Table 1.
Themajority of patients exhibited systemic hypertension as a
cause of HF. Of the patients studied, 83%were in NYHA class
II symptoms at the time of admission. All HFpEF patients
exhibited a larger LV end-diastolic volume and a shorter
peak filling rate (PFR) with a higher time to PFR compared
with the healthy subjects confirming a significant diastolic
dysfunction in our patients. LVEF was higher in patients
withHFpEF.Themajority of patients (67%) were treated with
4 International Journal of Vascular Medicine
Table 2: Exercise haemodynamics and gas exchange parameters for the study population.
Stress variables HFpEF patients(𝑛 = 18)
Healthy controls
(𝑛 = 14)
Duration (min) 8.33 ± 0.48∗ 10.36 ± 0.55
Maximal energy expenditure (METS) 4.81 ± 0.21∗∗∗ 8.07 ± 0.48
Peak exercise heart rate (bpm) 106 ± 5∗∗∗ 162 ± 6
Peak exercise systolic blood pressure (mmHg) 158 ± 6∗ 180 ± 7
Peak exercise diastolic blood pressure (mmHg) 74.1 ± 1.9 79.6 ± 2.2
Peak VO2 (mL/kg/min) 12.0 ± 0.44∗∗∗ 19.1 ± 1.07
% of VO2 predicted for age 87 ± 5∗∗∗ 123 ± 6
Heart rate recovery at 1min (bpm) 17.0 ± 2.2∗ 24.4 ± 2.6
Heart rate recovery at 2min (bpm) 32.1 ± 3.1∗∗∗ 50.0 ± 3.6
VE/VCO2 slope 33.6∗ 29.3
OUES 1.55 ± 0.12∗ 2.06 ± 0.14
METS: metabolic equivalent tasks; OUES: oxygen uptake efficiency slope; VCO2: exhale carbon dioxide; VE: ventilation; VO2: oxygen uptake. Values are
expressed as adjusted mean ± standard error or adjusted geometric mean. ∗𝑃 < 0.05; ∗∗∗𝑃 < 0.001. For the VE/VCO2 slope variable, there was a significant
interaction age ∗ group. In this table, we present the adjusted geometric means for an age of 68 years (median value) which is the closest age compared with
our HFpEF patients. For𝑄1 (61 year old), there was no significant difference between HFpEF patients and healthy control subjects (30.9 versus 29.7, 𝑃 = 0.57).
For𝑄3 (75 year old), there was a significant difference between HFpEF and healthy control subjects (36.7 versus 28.9, 𝑃 < 0.01).
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Figure 1: Circulating biomarker levels for patients with HFpEF versus healthy control subjects. NT-proBNP: N-terminal prohormone of
brain natriuretic peptide; hsCRP: high-sensitivity C-reactive protein; TBARS: thiobarbituric acid reactive substances. Values are expressed as
adjusted geometric mean or adjusted mean ± error. Significantly different from HFpEF values: ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001.
an angiotensin II receptor blocker (ARBs) and 50% received
a beta-blocker.
Exercise and gas exchange parameters are presented
in Table 2. All patients and healthy subjects performed a
maximal effort as evidenced by a respiratory exchange ratio
>1.05 (data not shown). Exercise duration and peak METS
achieved were significantly lower in patients with HFpEF
compared with healthy subjects. The OUES was reduced by
31% in our patients. Similarly, peak VO
2
and the VE/VCO
2
slope were significantly decreased by 41% and increased by
15%, respectively. HRR at 1 and 2min after the termination of
exercise were significantly lower in patients compared with
the healthy subjects.
Biomarkers data for the study population are presented
in Figures 1 and 2. Plasma levels of hsCRP (𝑃 < 0.05),
TBARS (𝑃 < 0.01), and 8-epi-prostaglandin F2𝛼 (𝑃 < 0.05)
were significantly increased in patients with HFpEF com-
pared with healthy subjects. The patients exhibited a 4-fold
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Table 3: Correlations between biomarkers and peak VO2 for the study population.
Peak VO2 HRR 2 BNP hsCRP IL-6 8-epi-PG-F2𝛼 TBARS
Pearson correlation coefficients (𝑃 values)
Peak VO2 1
HRR 2 0.71∗∗∗ 1
BNP −0.66∗∗∗ −0.57∗∗∗ 1
hsCRP −0.40∗ −0.49∗∗ 0.45∗ 1
IL-6 −0.63∗∗∗ −0.57∗∗∗ 0.70∗∗∗ 0.67∗∗∗ 1
8-epi-PG-F
2𝛼
−0.41∗ −0.38∗ 0.44∗ 0.21 0.55∗∗ 1
TBARS −0.22 −0.19 0.26 0.39∗ 0.41∗ 0.43∗ 1
BNP: brain natriuretic peptide; HRR2: heart rate recovery at 2min following the end of exercise; hsCRP: high-sensitivity C-reactive protein; IL-6: interleukin-
6; TBARS: thiobarbituric acid reactive substances; VO2: oxygen consumption; 8-epi-PG-F2𝛼: 8-epi-prostaglandin F2𝛼.
∗
𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001.
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Figure 2: Changes in brain natriuretic peptide at rest and at peak
exercise in patients with HFpEF versus healthy subjects. BNP: brain
natriuretic peptide. Values are expressed as adjusted geometric
mean. Significantly different from HFpEF values: ∗∗𝑃 < 0.01.
increase in NT-proBNP (𝑃 < 0.001) (Figure 1) and a 3-fold
increase in BNP plasma concentrations (𝑃 < 0.01) in resting
state (Figure 1). This difference persisted at peak exercise
(Figure 2).
The relationships between biomarkers with selected exer-
cise and biochemistry parameters are presented in Table 3
andFigure 3. Significant relationshipswere observed between
BNP, hsCRP, IL-6, and 8-epi-prostaglandin F2𝛼 and peak
VO
2
and HRR 2 (Table 3). There was also a modest but
significant relationship betweenhsCRP and IL-6 and between
hsCRP and exercise duration in the HFpEF population
(Figure 3).
Peripheral arterial flows in resting state and following
arterial occlusion are presented in Figure 4. Basal peripheral
arterial forearm blood flow was not statistically different in
the study population as demonstrated by the area under
the curve (AUC) in HFpEF patients compared with healthy
subjects (resp., 523±70 versus 386±41, NS) (Figure 4(a)). No
difference in the hyperemic response was observed between
the two groups (Figure 4(b)).
4. Discussion
In this study we reported a significant reduction in aerobic
capacity and oxygen uptake efficiency in ambulatory patients
with HFpEF. We also reported a significant increase in some
biomarkers related to subclinical inflammation and oxidative
stress. Both BNP and NT-proBNP were significantly elevated
at rest with a similar magnitude of BNP increase at peak
exercise in both patients and healthy subjects. In addition,
we observed some significant relationship between peak
aerobic capacity and HRR following exercise with BNP, IL-
6, and 8-epi-prostaglandin F2𝛼. We observed no significant
differences in basal and posthyperemic blood flow in HFpEF
patients compared with healthy subjects.
Previous investigations have reported a significant reduc-
tion in functional and peak aerobic capacities in patients
with HFpEF [2, 18–20]. Here we reported a decrease in peak
VO
2
of 37% in patients with HFpEF compared with controls.
This magnitude of decrease is in agreement with the overall
decrease of 40% reported by other investigators [2, 18–20].
In addition, we observed a 30% reduction in the OUES
in HFpEF patients compared with healthy control subjects.
These changes are consistent with previous reports [2, 20]
showing significant decrease in cardiopulmonary reserve and
abnormal ventilator function in these patients.
Previous investigations have shown an increase in
selected biomarkers such as IL-6 and NT-proBNP in patients
with HFpEF [7, 8, 21]. Our findings confirm our former
observations and data from other investigators showing
significant increases of the C-reactive protein and IL-6 and
demonstrating a significant proinflammatory state in these
patients [7, 21, 22]. In addition to earlier studies [23, 24],
we reported a 3-fold increase in BNP at rest which was
maintained at peak exercise in HFpEF patients. The similar
magnitude of BNP increase at peak exercise for both HF
and health subjects patients suggests a preservation of wall
stress during exercise in patients with HFpEF. Here we
also reported a significant increase in biomarkers related
to oxidative stress in patients with HFpEF compared with
healthy subjects. These findings have not been reported
before. Indeed, two biomarkers of oxidative stress including
TBARS and 8-epi-prostaglandin F2𝛼 were both significantly
increased, confirming a prooxidative state in these patients.
Previous investigations have reported a role of oxidative stress
in the pathophysiology of HF [25, 26]. Other observations
have reported a detrimental effect of oxidative stress on the
degradation of cardiac extracellular matrix degradation in
6 International Journal of Vascular Medicine
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Figure 3: Relationships between selected inflammatory biomarkers and exercise duration in patients with HFpEF. hsCRP: high-sensitivity
C-reactive protein; 𝑅2: coefficient of determination.
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Figure 4: Changes in basal (a) and hyperemic (b) arterial blood flow for patients with HFpEF versus healthy control subjects. Values are
expressed as adjusted mean ± standard error.
humans [27] and on the cardiac contractility in mice [28].
The role of biomarker changes and specially those related to
subclinical inflammation and oxidative stress on the patho-
physiology of HFpEF remain unknown. We further explored
the relationships between selected clinical and functional
parameters with some biomarkers in our study population.
We reported a significant relationship between peak VO
2
and HRR at 2 minutes with BNP, 8-epi-prostaglandin F2𝛼,
hsCRP, and IL-6 in the overall population.This suggests a sig-
nificant relationship between inflammation and autonomic
regulation with functional capacity in HFpEF patients. These
observations are in agreement with previous studies showing
a relationship between sympathetic and parasympathetic
tones and regulation of inflammation in chronic HF patients
[29] and in a canine pacing model of HF [30]. Additional
investigations are needed to confirm these findings.
Here, we reported no significant differences in basal
and posthyperemic peripheral arterial blood flow in patients
with HFpEF compared with healthy subjects. Abnormal
endothelial function is associated with a decreased aerobic
capacity in high risk patients [9] and in patients with
HF with decreased LVEF [12]. There has been little data
regarding the changes in peripheral arterial blood flow at
rest and following stress in patients with HFpEF. A previous
investigation reported a decrease in leg blood flow at rest
and following exercise [1]. In contrast, other clinical studies
reported no difference in leg flow-mediated dilation [11]
or in brachial artery flow-mediated dilation [10] following
submaximal exercise compared with healthy subjects. In that
same study, no significant relationship between the reduction
in peak VO
2
and brachial artery flow-mediated dilation has
been reported beyond the effect of aging [10].The differences
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between a previous study [1] and our data may be explained
by some clinical differences in the patient population and
methodological approaches. First, the etiology of HF was
different with some patients presenting dyspnea because of
bronchial asthma in the latter study [1].Most importantly, the
rate of use of angiotensin-II modulating agents was 73% in
the current study as opposed to 40% on average in previous
publications [1, 10]. The high proportion of use of ARBs
(i.e., 67%) may have contributed to attenuate the changes in
basal and posthyperemic blood flow in our patients [31, 32].
Finally, we used SGP as opposed to magnetic resonance
[1, 11] or brachial artery flow-mediated dilation [10] methods.
Contrary to these techniques, we mechanically assessed the
increase in forearm volume after the cuff deflation using
calibrated strain gauges connected to a plethysmograph.This
technique correlates well with the near-infrared spectroscopy
for noninvasive assessment of arterial forearm flow [17].
Nevertheless SGPmay not be sensitive enough to detect small
changes in microvascular function in HFpEF patients.
Several factors may limit the conclusions of this study.
Firstly, the population of patients was older than the control
population. However, to minimize the impact of age on
our observations ANCOVA analyses were computed using
age as a covariate. Also no investigations have reported any
effect of age on biomarkers and functional parameters in
patients with symptomatic HF caused by preserved ejection
fraction. Secondly, the sample size was small. Despite this,
our study population was fairly homogenous allowing small
variance and significance in most of the parameters studied.
Thirdly chronic use of ARBs may have significantly impacted
our findings on forearm blood flow data. Finally, we only
measured plasma level of BNP at peak exercise.The inclusion
of other biomarkersmay have provided additional insights on
the mechanisms involved with exercise limitations in these
patients.
In conclusion, this study demonstrates that ambulatory
patients with HFpEF exhibit a significant reduction in car-
diopulmonary reserve and oxygen uptake efficiency con-
comitantly with an elevation in broad spectrum of biomark-
ers confirming a proinflammatory and a prooxidative status
in these patients. The relationship between some biomarkers
of inflammation and oxidative stress suggest a role of these
processes on functional capacity in these patients.The role of
biomarkers and the assessment of peripheral arterial function
by multimodality techniques deserve further investigations.
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